Switch Therapeutics
Don is Vice President, Biology at Switch Therapeutics and works closely with the technology platform development team to utilize Switch’s unique RNAi therapeutics for making new drugs to address unmet medical needs. He trained as a molecular pharmacologist and has 20+ years of industry experience in drug discovery and development, focused on orally available small molecules, protein therapeutics and oligonucleotide drugs for indications in the central nervous system, cardiovascular and immune systems
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.